A Colorado family is calling for change and sharing their struggle after a clinical trial their son relied on suddenly ended.

Quotient Sciences extends commercial manufacturing partnership with Ipsen for an ultra-rare disease treatment: Philadelphia, Pennsylvania Saturday, February 28, 2026, 10:00 Hrs [I ...

The companies have extended a commercial supply partnership for the manufacture of Sohonos (palovarotene), which is a ...

The agreement includes Ipsen’s investment in additional equipment at Quotient Sciences’ facility in Boothwyn, Pennsylvania, ...

Expands Quotient's capabilities for handling and manufacturing highly potent API (HPAPI) drug molecules and products.

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is one of the best value stocks to buy now. On February 19, Regeneron Pharmaceuticals announced that the FDA accepted its BLA for garetosmab for Priority ...

Garetosmab is a fully-human monoclonal antibody designed to bind and neutralize Activin A, a major promoter of heterotopic ossification in patients with FOP.

FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approve ...

FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If ...

Regeneron Pharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking approval of garetosmab for adults with the ultra-rare genetic disorder fibrodysplasia ...

Imagine a bruise that never heals — instead, it hardens into bone. A small swelling that doesn’t fade but permanently locks a ...

Add Yahoo as a preferred source to see more of our stories on Google. Federal Protective Service vehicles are parked outside the Everett McKinley Dirksen United States Courthouse in Chicago, Oct. 9, ...